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Abstract
Background: In cancer cells, transcriptional gene silencing has been associated with genetic and epigenetic
defects. The disruption of DNA methylation patterns and covalent histone marks has been associated with cancer
development. Until recently, microRNA (miRNA) gene silencing was not well understood. In particular, miR-125b1
has been suggested to be an miRNA with tumor suppressor activity, and it has been shown to be deregulated in
various human cancers. In the present study, we evaluated the DNA methylation at the CpG island proximal to the
transcription start site of miR-125b1 in cancer cell lines as well as in normal tissues and gynecological tumor
samples. In addition, we analyzed the association of CTCF and covalent histone modifications at the miR-125b1
locus.
Methods: To assess the DNA methylation status of the miR-125b1, genomic DNA was transformed with sodium
bisulfite, and then PCR-amplified with modified primers and sequenced. The miR-125b1 gene expression was
analyzed by qRT-PCR using U6 as a control for constitutive gene expression. CTCF repressive histone marks
abundance was evaluated by chromatin immunoprecipitation assays.
Results: The disruption of CTCF in breast cancer cells correlated with the incorporation of repressive histone marks
such H3K9me3 and H3K27me3 as well as with aberrant DNA methylation patterns. To determine the effect of DNA
methylation at the CpG island of miR-125b1 on the expression of this gene, we performed a qRT-PCR assay. We
observed a significant reduction on the expression of miR-125b1 in cancer cells in comparison with controls,
suggesting that DNA methylation at the CpG island might reduce miR-125b1 expression. These effects were
observed in other gynecological cancers, including ovarian and cervical tumors.
Conclusions: A reduction of miR-125b1 expression in cancers, correlated with methylation, repressive histone
marks and loss of CTCF binding at the promoter region.
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Background
MicroRNAs (miRNAs) are a broad family of small non-
coding RNAs and are involved in multiple cellular pro-
cesses [1]. In mammals, miRNAs have been predicted to
control the transcriptional activity of more than 60% of
protein-encoding genes [2]. Therefore, miRNAs repre-
sent a new component associated with the regulation of
gene expression [3]. The study by Sato and collaborators
has gained importance because many miRNAs function
as tumor suppressor genes and oncogenes and because
their deregulation can lead to the development of cancer
[3]. This phenomenon has been observed in lung, colon
and breast cancer, among others. The deregulation of
miRNAs is associated with both genetic and epigenetic
defects [4,5]. Some miRNAs have been described to
have an oncogenic function, such as miR-17-92, miR-
155 and miR-372-373, and can influence cell prolifera-
tion, whereas others present tumor suppressor gene
activity, e.g., as miR-34, miR-26a and miR-125b [2,6-8].
In particular, the expression of miR-125b1 was
observed to be decreased in glioblastoma, prostate
* Correspondence: herreram@biomedicas.unam.mx
1Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de
Cancerología (INCan)-Instituto de Investigaciones Biomédicas, Universidad
Nacional Autónoma de México (UNAM), México, DF, México
Full list of author information is available at the end of the article
Soto-Reyes et al. BMC Cancer 2012, 12:40
http://www.biomedcentral.com/1471-2407/12/40
© 2012 Soto-Reyes et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.cancer, ovarian cancer and breast cancer. Interestingly,
in vitro studies suggest that miR-125b1 targets HER2/
neu and ESR1 genes, two genes important for the diag-
nosis and treatment of breast cancer [9,10]. One of the
mechanisms associated with epigenetic silencing of miR-
125b1 is DNA methylation [8]. Particularly, a hyper-
methylation of a CpG island located in proximity to the
transcription initiation site was observed in cell lines
and in tissue samples from patients with breast cancer
[8,11].
It is now known that a multifunctional CCCTC-bind-
ing factor (CTCF) can serve as a barrier against the
spread of DNA methylation and histone repressive marks
over promoter regions of tumor suppressor genes. CTCF
has been involved in many aspects of epigenetic regula-
tion, such as X chromosome inactivation, genomic
imprinting, regulation of non-coding transcripts and the
structure and function of repeated elements [12,13].
CTCF has been involved in the epigenetic regulation
of genes related to cell cycle control, such as BRCA1,
Rb, p16 and p53 [14-18]. Recently, CTCF has also been
shown to be involved in the regulation of miRNAs [19].
Therefore, CTCF may be able to protect against DNA
methylation and the covalent incorporation of negative
marks on histones in miRNAs with CpG islands [19].
The aim of the present study was to evaluate the DNA
methylation at the CpG island proximal to the transcrip-
tion start site of miR-125b1 in cancer cell lines as well
as in normal tissues and gynecological tumor samples.
In addition we analyzed the association of CTCF and
covalent histone modifications at the miR-125b1 locus.
We found that the miR-125b1 CpG island is methy-
lated in cancer cells. The disruption of CTCF combined
with DNA methylation and the gain of repressive his-
tone covalent marks, such as H3K9me3 and H3K27me3,
result in the miRNA gene silencing.
Methods
Cell culture conditions
MCF-7, SK-BR-3, MCF10A and MDA-MB-231 cells
were cultured in Dulbecco’s modified Eagle’sm e d i u m
DMEM (Invitrogen) with 10% fetal bovine serum (Invi-
trogen) and 1% penicillin/streptomycin (Invitrogen,
Carlsbad, CA, USA). All cells were grown in a humidi-
fied incubator at 37°C with 5% CO2.
Tissue specimens and processing
All breast, ovarian and cervical cancer samples were
obtained from the Instituto Nacional de Cancerología de
México and classified according to the American Joint
Committee on Cancer (AJCC) using the tumor-lymph
node-metastasis (TNM) system. Diagnosis was given by
trained pathologists from the institute based on WHO
classification. Nine breast cancer samples, four ovarian
cancer samples and three cervical cancer samples were
obtained prospectively. These samples were obtained
from untreated patients. As controls we analyzed three
normal breast samples from mammoplasty surgeries,
one normal ovarian sample from a hysterectomy indi-
cated by cystocele, and one normal cervical sample from
a healthy woman. Fresh samples were preserved at -20°
C in RNAlater (Qiagen). Tissue sections were stained
with H&E and were used only if they contained more
than 70% cancer cells. This study was approved by the
ethical committee of the Instituto Nacional de Cancero-
logía (approval numbers 011/034/IBI and CB/727).
Bisulfite sequencing and MS-PCR for the miR-125b1
promoter
DNA from tumor samples and cell lines were obtained
by phenol/chloroform extraction. Two micrograms of
genomic DNA was modified using the EZ methylation
kit (ZYMO). For sequencing, modified DNA was sub-
jected to PCR using oligonucleotides to amplify from
the 573 to 303 positions upstream the transcription
start site of miR-125b1 (Entrez Gene: 406911). We used
the following primers for amplification (270 bp), F: 5’-
TGGTGTTATAGGAGGTTGTG-3’;a n dR :5 ’-ACCC-
AAATTTTTAAAACCATAA-3’.P C Rp r o d u c t sw e r e
purified with the DNA clean and concentrator kit
(ZYMO Research). The products were cloned into the
pGEM-T-Easy vector (Promega). At least sixth clones
were selected randomly for DNA sequencing.
MS-PCR was performed with DNA treated with
sodium bisulfite. The following primers were designed
using MethPrimer software. For methylation analysis
MSPmet125b1F 5’-TGGTGTATCGTTTTTTGTTTTC-
3’ and MSPmet125b1R 5’-ACCCATTCGAAACGAAAC,
and for unmethylated analysis MSPunm125b1F 5’-
ATTTGGTGTATTGTTTTTTGTTTTT and MSPunm-
125b1R 5’-CTCACCCATTCAAAACAAAAC. As a posi-
tive control, 1 μg of DNA from lymphocytes of a healthy
donor was methylated in vitro (IVD) for eight hours
using SssI methyltransferase (NEB, Beverly, MA).
ChIP assay
Standard chromatin immunoprecipitation (ChIP) assays
were performed as previously reported [18] with 4 μgo f
the following antibodies: H3K4me2 (07-030, Millipore);
H3K9me2 (ab8898, Abcam); H3K27me3 (ab6002,
Abcam), and CTCF (07-729, Millipore). As negative
control we employed a normal rabbit IgG (sc-2027,
Santa Cruz Biotechnology). Immunoprecipitated DNA
was analyzed by PCR using specific primers to analyze
the four genomic regions, including the miR-125b1 pro-
moter. The 5’ p53 gene promoter was used as positive
control for CTCT’s ChIP [18]; and for the H3K27me3
histone mark we analyzed the Myelin transcription
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used for ChIP assays are available by request.
Quantitative real-time RT-PCR (qRT-PCR)
Total RNA was extracted with Trizol (Invitrogen). The
miRNA levels were determined by qRT-PCR performed
w i t hc D N Ag e n e r a t e df r o m1 0n go ft o t a lR N Au s i n g
the TaqMan
® miRNA Reverse Transcription Kit
(Applied Biosystems). To evaluate the expression of the
mature miR-125b1, we employed the TaqMan
® primer
ID 002378 (Applied Biosystems). The relative amount of
miR-125b1 was normalized against U6 snRNA (ID
001093), and the fold change was calculated by the 2-
ΔΔCt method. The amplification and detection of speci-
fic products were performed with the ABI PRISM 7000
system (Applied Biosystems).
Statistical analysis for qRT-PCR
Data from at least four independent experiments are
expressed as the mean ± standard deviation. The differ-
ences between groups were analyzed using the Student’s
t-test comparing the cancer cell lines with a non-
tumorigenic epithelial cell line (MCF10A), and breast
tumor with normal breast samples. Data were consid-
ered significant if p < 0.001.
Results
DNA methylation profile of the miR-125b1 CpG island in
breast cancer cell lines
As a first approach, we conducted an in silico study of
the locus of miR-125b1. This miRNA is located on the
long arm of chromosome 11 (11q24.1). Let-7a2 miRNAs
and miR-100 are located upstream of this gene. In addi-
tion, there is a CpG island upstream from the transcrip-
tion start site of miR-125b1 (Figure 1A). The DNA
methylation status of the CpG island was assessed
through sodium bisulfite conversion and MS-PCR in
various transformed cell lines (Figure 1B). Using syn-
thetic oligonucleotides modified for DNA methylation
analysis, we determined that the CpG island associated
with miR-125b1 is methylated in most breast tumor cell
lines, with the exception of SK-BR-3 (Figure 1B, C).
DNA from the non-transformed breast cell line
MCF10A and DNA methylated in vitro by the enzyme
S s sI( I V D )w e r eu s e da sc o n t r o l s( F i g u r e1 B ) .T h e s e
data suggest that DNA methylation of the miR-125b1
CpG island primarily occurs in transformed cell lines (i.
e., MDA-MB-231 and MCF7). To confirm the DNA
methylation status, we cloned and sequenced the pro-
duct of sodium bisulfite conversion (Bs-seq) for the
MDA-MB-231, MCF7, SK-BR-3 and MCF10A cell lines
(Figure 1C). The results showed that these cell lines had
different densities of DNA methylation, with partial
methylation in MDA-MB-231 and in MCF7. In contrast,
SK-BR-3 and the control, MCF10A, showed no methyla-
tion at the miR-125b1 promoter. These results suggest
that DNA methylation of the miR-125b1 CpG island
occurs mostly in transformed cells. In order to deter-
mine the effect of DNA methylation at the CpG island
of miR-125b1 on the expression of this gene, we per-
formed a qRT-PCR assay (Figure 1D). We observed a
significant reduction on the expression of miR-125b1 in
MCF7 and MDA-MB-231 in comparison with MCF10A,
suggesting that DNA methylation at the CpG island
might reduce miR-125b1 expression (Figure 1D). To
confirm this hypothesis, we extended our study to sam-
ples from human gynecological tumors.
DNA methylation profile at the miR-125b1 CpG island in
primary gynecological tumor samples
Tumor samples were collected from breast (n = 9),
ovarian (n = 4) and cervical tumors (n = 3) DNA was
extracted from these samples and treated with sodium
bisulfite. Subsequently, the DNA methylation status of
the promoter of miR-125b1 was analyzed by MS-PCR.
The methylation status for the breast tumor samples
varied, 23% were totally methylated, 66% were partially
methylated and only 11% showed no DNA methylation
at the CpG island region of miR-125b1. As a control, we
used normal breast tissue samples obtained from aes-
thetic mammoplasties. These control samples were ana-
lyzed by MS-PCR and Bs-seq, and no DNA methylation
was detected in them (Figure 2A, B).
All together, these results suggest that DNA methyla-
tion at the CpG island of miR-125b1 occurs in tumors
and could be involved in cancer development.
We then used this assay to analyze the methylation
status in four ovarian cancer samples and three from
cervical cancer. We observed DNA methylation of miR-
125b1 in all samples from gynecological tumors except
for one breast cancer sample, suggesting that this epige-
netic modification is present only in transformed cells.
Therefore, we evaluated the effect of the methylation at
the CpG island on the expression of miR-125b1 in
breast cancer samples by qRT-PCR. We found a signifi-
cant decrease in miR-125b1 expression in breast cancer
samples, BC1 and BC8, and a marginal reduction in
BC9 sample compared with normal breast tissue. These
results suggest that DNA methylation at the miR-125b1
CpG island decreases significantly the miRNA in human
breast cancer samples. While the marginal reduction
observed in sample BC9 could suggest that other epige-
netic process might also be involved.
Characterization of CTCF and histone marks across the
miR-125b1 locus in normal and breast tumor samples
Because CTCF has been proposed to protect genomic
regions against DNA methylation, we decided to
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Figure 1 Correlation between DNA methylation and expression status of miR-125b1 in breast cancer cell lines. A-S c h e m a t i c
representation of the locus of miR-125b1. Circles represent the CTCF binding sites, open circles represent the CpG island (CGI) present upstream
of miR-125b1 and arrows represent the transcription start site. The regions amplified by PCR for the chromatin immunoprecipitation (ChIP) assay
are represented in arrows and named by regions as RI to RIV. B- Assessment of DNA methylation status using MS-PCR of miRNAs in the breast
cancer cell lines SK-BR-3, MDA-MB-231 and MCF7. As a control for the technique, we assessed the methylation state of DNA from non-
tumorigenic epithelial cell line MCF 10A. DNA from lymphocytes was methylated in vitro by SssI methyltransferase, and used as a positive
methylated DNA. M represents methylated, and U represents non-methylated. C- Determination of the DNA methylation status using sodium
bisulfite and sequencing in breast cancer cell lines. Black boxes represent methylated CpGs, and white boxes represent non-methylated CpGs.
D- Expression analysis of miR-125b1 in breast cancer cell lines compared with MCF 10A.P < 0.001 Student’s t-test.
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Figure 2 Analysis of the DNA methylation status in normal tissue and gynecological tumor samples. A- Analysis of DNA methylation by
MS-PCR in several normal breast (NB), ovary (NO), cervix (NC) and peripheral blood lymphocytes (NL). Assessment of DNA methylation state in
various gynecological primary tumors: Breast cancer (BC), ovarian cancer (OC) and cervical cancer (CC). B- Determination of the DNA methylation
status using sodium bisulfite and sequencing in primary breast cancer samples and normal tissue samples. Black boxes represent methylated
CpGs, and white boxes represent non-methylated CpGs. C- Expression analysis of miR-125b1 from primary breast cancer samples compared with
normal breast tissue obtained during an aesthetic mammoplasty. **P < 0.001 Student’s t-test.
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Page 5 of 9evaluate the presence of this factor using a ChIP assay
in cells from normal breast tissue and from two breast
cancer samples (Figure 2). This study was extended to
four genomic regions of the locus of miR-125b1 (Figure
1A, RI-RIV). In addition, we analyzed the same regions
for the presence of several covalent histone modifica-
tions such as H3K4me2, a histone mark associated with
open chromatin, and the repressive histone marks
H3K9me3 and H3K27me3 (Figure 3). An anti-IgG was
included as negative control. For this assay, we used
four different sets of primers, which amplified three
regions located 3’ and 5’ from the miR-125b1 promoter,
where it has been shown that CTCF binds in vivo [21].
In addition, we also used primers corresponding to the
promoter region of the gene (Figure 1A). As a positive
ChIP assay control for CTCF we evaluated the human
p53 gene promoter in all our ChIPs, and for the
H3K27me3 histone mark we analyzed the presences of
this histone mark at the Myelin transcription factor 1
distal promoter (MYT1) region (Figure 3C).
In normal breast tissue, we observed CTCF enrichment
in the four genomic regions, suggesting that this factor is
probably linked to the chromatin structure and regula-
tion of the miR-125b1 locus in cells from normal breast
tissue (Figure 3A). Subsequently, we obtained chromatin
from two breast tumors samples. Using the ChIP assay,
we analyzed the covalent histone marks H3K4me2,
H3K9me3 and H3K27me3. In the breast tumor cells we
observed the loss of CTCF in all regions analyzed (Figure
3B). The gain of the negative histone mark H3K9me3
was observed in all regions in BC9 and in regions I and
IV in BC8, while H3K27me3 was only observed in RI of
BC8 (Figure 3B). These data strongly suggest that the
absence of CTCF, together with DNA methylation and
some histone repressive marks may contribute to the
destabilization of chromatin permissive for transcription
and the establishment of an aberrant repressive chroma-
tin configuration of the miR-125b1 locus.
Discussion
Cancer is primarily a disease that consists of the accu-
mulation of genetic and epigenetic alterations. The epi-
genetic alterations can lead to the inactivation of tumor
suppressor genes and the activation of oncogenes.
Because some miRNAs target genes involved in cell
cycle control, they have been associated with the func-
tions of tumor suppressor genes and oncogenes [22].
Currently, there is experimental evidence that aberrant
patterns of DNA methylation and repressive covalent
histone modifications in the promoter regions of miR-
NAs associated with CpG islands can lead to epigenetic
silencing [4]. Some studies have suggested that the loss
of DNA methylation in the promoters of some miRNAs
(e.g., miR-21, miR-203 and miR-205) in ovarian cancer
results in their aberrant overexpression [23]. On the
other hand, it has been shown that DNA hypermethyla-
tion in the promoters of miR-124a and miR-127 leads to
their transcriptional silencing in colon cancer models
and influences the expression of two oncogenes, such as
BCL6 and CDK6 [4]. The epigenetic silencing of miR-
NAs has been frequently observed in early stages of
breast cancer, including miR-9-1 and the miRNAs of
the Let-7 family. Therefore, miRNAs could be good can-
didates for early tumor markers [24]. Furthermore, some
miRNAs have been associated with invasion and metas-
tasis in breast cancer [25]. One of the miRNAs that are
deregulated in breast cancer is miR-125b1, and its
expression is reduced in this type of cancer, suggesting
its importance [10,26].
In the present study, we showed that methylation of
DNA in a CpG island upstream of the transcription
start site of miR-125b1 and the gain of repressive his-
tone marks, such as H3K9me3 and H3K27me3, is a
mechanism for the epigenetic silencing of this miRNA.
W ef o u n dt h a tD N Am e t h y l a t i o na tt h eC p Gi s l a n do f
miR-125b1 is present in the evaluated gynecological
tumors. Our results suggest that this methylation nega-
tively affects the miRNA gene expression, indicating that
it could be in part responsible for the gene inactivation
(Figures 1 and 2).
One of the most studied proteins in vertebrates is the
nuclear factor CTCF [27]. This protein has the ability to
delimit chromosomal borders, which affect the distinction
of transcriptionally active regions from more compact
regions in which transcription is repressed. It is currently
accepted that CTCF can contribute to the establishment
of chromatin domains. This organization promotes the
creation of a local chromatin that facilitates communica-
tion between regulatory elements, such as promoters or
enhancers [28]. Because CTCF has been related with pro-
tection against DNA methylation and repressive histone
marks propagation, we investigated whether the presence
of CTCF is associated with the transcription of miR125-
b1. Interestingly, in normal breast cells, CTCF is distribu-
ted along the locus miR-125b1, whereas in primary breast
tumors, we observed the absence of this factor. These data
suggest that the absence of CTCF may be related to a gain
of aberrant DNA methylation in the CpG island and a
gain of repressive histone marks along the four genomic
regions studied (Figure 3).
Therefore, we propose that the absence of CTCF
along a locus may result in the loss of transcriptionally
active borders, and together with DNA methylation and
some histone repressive marks, such as H3K27me3,
could promote the epigenetic silencing of the miRNA
(Figure 4).
Some authors have referred to CTCF as the “glue”
that connects the ends of domains, both intra- and
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Figure 3 In vivo CTCF binding analysis in miR-125b1 locus and the characterization of covalent histone marks in both normal cells
and in primary breast tumors. A- Chromatin immunoprecipitation (ChIP) of CTCF and the histone covalent marks analyzed at the human miR-
125b1 locus in cells obtained from normal breast tissue (NB 1). B- Characterization of CTCF and histone covalent marks in two tumor samples
tissue from different patients (BC8 and BC9), input amplification refers as the entire population of DNA. A non-specific IgG antibody was used as
a control. C- Positive controls for the ChIP assay. For CTCF we performed a PCR of the p53 gene promoter region in normal breast (NB1) and
two tumor samples (BC8 and BC9); for H3K27me3 we evaluated the abundance of the H3K27me3 histone mark at the Myelin transcription factor
1 distal promoter (MYT1) region in two tumor samples (BC8 and BC9).
Soto-Reyes et al. BMC Cancer 2012, 12:40
http://www.biomedcentral.com/1471-2407/12/40
Page 7 of 9inter-chromosomally, thus suggesting that deregulation
of this factor leads to the aberrant silencing of multiple
genes, including miRNAs [29]. These observations are
consistent with published data that demonstrate that
miR-125b1 can be silenced by DNA methylation, which
may lead to a worse prognosis in cancer patients [8].
Conclusions
Our results suggest that a reduction of miR-125b1
expression in cancers, is correlated with methylation,
repressive histone marks and loss of CTCF binding at
the promoter region.
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